持续葡萄糖监测与替代标志物评估慢性肾脏病中的血糖情况
这项前瞻性队列研究纳入104例2型糖尿病患者(80例eGFR<60 mL/min/1.73 m²且未透析,24例eGFR≥60 mL/min/1.73 m²对照),比较HbA1c、糖化白蛋白和果糖胺与持续葡萄糖监测(CGM)所测平均葡萄糖的相关性、变异性和协变量偏倚。HbA1c在白蛋白尿患者中被低估。结论支持在eGFR<60 mL/min/1.73 m²患者中检测HbA1c以监测血糖趋势,而直接测量葡萄糖对于捕捉短期变异性是必要的。
要点
- 糖化白蛋白和果糖胺在给定平均CGM葡萄糖水平下变异性不亚于HbA1c,且存在多个额外偏倚来源。
- HbA1c在白蛋白尿患者中被低估。
- 在eGFR<60 mL/min/1.73 m²患者中支持检测HbA1c以监测血糖趋势。
核心结论
- 糖化白蛋白和果糖胺在给定平均CGM葡萄糖水平下变异性不亚于HbA1c,且存在多个额外偏倚来源。
- 这些结果支持在eGFR<60 mL/min/1.73 m²患者中检测HbA1c以监测血糖趋势。
- 直接测量葡萄糖对于捕捉短期变异性是必要的。
研究设计与样本
- 前瞻性队列研究纳入104例2型糖尿病患者,其中80例eGFR<60 mL/min/1.73 m²(未接受透析治疗),24例频率匹配的对照受试者eGFR≥60 mL/min/1.73 m²。
- 参与者佩戴盲法CGM两个6天周期,间隔2周,每个CGM周期结束时采集血液和尿液。
- HbA1c、糖化白蛋白和果糖胺分别采用高效液相色谱法、酶法和比色硝基四氮唑蓝法测定。
主要发现
- 两个CGM周期之间的个体内生物标志物值强相关(r=0.92-0.95),但没有任何标志物完全捕捉平均CGM葡萄糖的个体内变异性。
- 与平均CGM葡萄糖相比,糖化白蛋白和果糖胺受年龄、BMI、血清铁浓度、转铁蛋白饱和度和白蛋白尿显著偏倚。
- HbA1c在白蛋白尿患者中被低估。
临床怎么用
- 作者结论认为这些结果支持在eGFR<60 mL/min/1.73 m²患者中检测HbA1c以监测血糖趋势。
- 作者指出直接测量葡萄糖对于捕捉短期变异性是必要的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In chronic kidney disease, glycated albumin and fructosamine have been postulated to be better biomarkers of glycemic control than HbA1c. We evaluated the accuracy, variability, and covariate bias of three biomarkers (HbA1c, glycated albumin, and fructosamine) compared with continuous glucose monitoring (CGM)-derived measurement of glycemia across estimated glomerular filtration rate (eGFR) in type 2 diabetes. RESEARCH DESIGN AND METHODS: A prospective cohort study was conducted of 104 participants with type 2 diabetes, 80 with eGFR <60 mL/min/1.73 m2 (not treated with dialysis) and 24 frequency-matched control subjects with eGFR ≥60 mL/min/1.73 m2. Participants wore a blinded CGM for two 6-day periods separated by 2 weeks, with blood and urine collected at the end of each CGM period. HbA1c, glycated albumin, and fructosamine were measured by high-performance liquid chromatographic, enzymatic, and colorimetric nitroblue tetrazolium methods, respectively. RESULTS: Within-person biomarker values were strongly correlated between the two CGM periods (r = 0.92-0.95), although no marker fully captured the within-person variability of mean CGM glucose. All markers were similarly correlated with mean CGM glucose (r = 0.71-77). Compared with mean CGM glucose, glycated albumin and fructosamine were significantly biased by age, BMI, serum iron concentration, transferrin saturation, and albuminuria; HbA1c was underestimated in those with albuminuria. CONCLUSIONS: Glycated albumin and fructosamine were not less variable than HbA1c at a given mean CGM glucose level, with several additional sources of bias. These results support measuring HbA1c to monitor trends in glycemia among patients with eGFR <60 mL/min/1.73 m2. Direct measurements of glucose are necessary to capture short-term variability.
引用
- Zelnick LR, Batacchi ZO, Ahmad I, et al. Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease. Diabetes Care. 2020. PMID: 32788282. doi:10.2337/dc20-0915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。